Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Event Details


Managing Cancer Immunotherapy Adverse Effects

Service development training and education for effective escalation and toxicity management

Add this event to your calendar: iCal   Google Calendar

Who should attend?

With limited budgets and opportunities to expand, you need to be creative in tackling the adverse effects of immunotherapy and educating both front line and ward staff. Now in its third year, this is a great opportunity for you to network with: Lead Nurses, CNS, Matrons and Sisters in Cancer, Acute Oncology and Chemotherapy Clinical Nurse Specialists in Lung Cancer, Gynaecology and Palliative Care Consultant Clinical Oncologists, Consultant Medical Oncologists and Speciality Doctors Pharmacists, Medical Managers and Service Managers


This third annual Managing Cancer Immunotherapy conference will be focusing on adverse effects providing a learning and networking platform to share good practice and resources. Designed for Clinical Oncologists, Medical Oncologists, Lead Nurses and Nurse Specialists from Acute Oncology and Cancer Services, and Chemotherapy and Respiratory Units, this is a great opportunity to increase understanding across your service of both the short and long-term side effects and put the right systems in place for appropriate escalation and care.


NHS or Public Sector for one place £399 + VAT NHS or Public Sector for two or three places (each) £299 + VAT NHS or Public Sector for four places (each) £279 + VAT Commercial Organisation for one place £699 + VAT


Georgie Orchard

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.